عرقگز
Sign in to saveIntertrigo, commonly called "skin fold dermatitis", refers to a type of inflammatory rash (dermatitis) of the superficial skin that occurs within a person's body folds. These areas are more susceptible to irritation and subsequent infection due to factors that promote skin breakdown such as moisture, friction, and exposure to bodily secretions and excreta such as sweat, urine, or feces. Areas of the body which are more likely to be affected by intertrigo include the inframammary fold, intergluteal cleft, armpits, and spaces between the fingers or toes. Skin affected by intertrigo is more prone
Key facts
- Medical condition (new).name
- Intertrigo
- Medical condition (new).image
- File:Axillary intertrigo.png
- Medical condition (new).caption
- Axillary intertrigo (bacterial)
- Medical condition (new).field
- Dermatology
via Wikipedia infobox
Health references
- ICD-10
- L30.4 — Erythema intertrigo
- MedlinePlus
- Consumer health page →
Source: U.S. National Library of Medicine (ICD-10-CM · MedlinePlus). Not medical advice.
Research
648 papers- The diagnosis, management and prevention of intertrigo in adults: a review.Journal of wound care · 2023
- Intertrigo.2026
- Recurrent candidal intertrigo: challenges and solutions.Clinical, cosmetic and investigational dermatology · 2018
- Intertrigo and common secondary skin infections.American family physician · 2005
- Streptococcal intertrigo.The Journal of pediatrics · 2015
via PubMed
Clinical Trials
19 registered- PHASE3COMPLETEDTopical Antifungal Treatment for Tinea CrurisMedicis Global Service Corporation · NCT01342315
- PHASE2COMPLETEDEvaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in PadarthamaraiNational institute of Siddha · NCT02238912
- PHASE2/PHASE3UNKNOWNEfficacy and Safety of Terbinafine and ItraconazoleDhaka Medical College · NCT05881980
- PHASE3COMPLETEDEvaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea CrurisMerz North America, Inc. · NCT01885156
- PHASE3COMPLETEDSafety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea CorporisTinea Pharmaceuticals · NCT01349998
- PHASE1COMPLETEDSafety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea PedisTherapeutics, Inc. · NCT05363449